1
|
Santos JDL, Bhisitkul D, Carman M, Wilson K, Hasara S, Homa K, Reyes P, Bugajski A, Barbera A. The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series. Int J Emerg Med 2022; 15:9. [PMID: 35240983 PMCID: PMC8892120 DOI: 10.1186/s12245-022-00414-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Accepted: 01/17/2022] [Indexed: 11/10/2022] Open
Abstract
Background Monoclonal antibody (MCA) therapies have been utilized under emergency use authorization (EUA) for high-risk pediatric patients with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting since late 2019. The purpose of this study was to describe the use of MCA therapy in pediatric patients in the pediatric emergency department (ED) at a large community hospital. Methods This was a retrospective case series of high-risk pediatric patients 12 to 17 years of age who received MCA therapy in the pediatric ED between December 8, 2020 and June 3, 2021. The primary outcome was to describe the patient characteristics, clinical presentation, and safety profile of the pediatric population that received MCA therapy. The secondary outcome was to describe the incidence of hospitalizations or ED visits up to 28 days following therapy. Results A total of 44 patients were included in the analysis. The median number of days of symptoms was 4 with 41% of patients having symptoms between 0 and 3 days at time of MCA administration. Only one patient experienced a mild adverse event that did not require epinephrine administration. Two patients returned to the ED for reevaluation during the study follow-up period. No patients required admission within 28 days post-therapy. Conclusions The administration of MCA therapy in high-risk pediatric patients in the pediatric ED was well-tolerated with subjective improvement noted in COVID-19 symptoms post-therapy. Further studies are necessary to determine the role MCA therapy may play in reducing morbidity from COVID-19 infection in high-risk pediatric patients.
Collapse
Affiliation(s)
- Jesse De Los Santos
- Department of Emergency Medicine, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| | - Donna Bhisitkul
- Department of Emergency Medicine, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| | - Matthew Carman
- Department of Emergency Medicine, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA.
| | - Kayla Wilson
- Department of Emergency Medicine, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| | - Shannon Hasara
- Department of Emergency Medicine, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA.
| | - Karen Homa
- Department of Research and Sponsored Studies, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| | - Pedro Reyes
- Department of Research and Sponsored Studies, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| | - Andrew Bugajski
- Department of Research and Sponsored Studies, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| | - Andrew Barbera
- Department of Emergency Medicine, Lakeland Regional Health, 1324 Lakeland Hills Blvd, Lakeland, FL, 33805, USA
| |
Collapse
|
2
|
Rudan I, Adeloye D, Katikireddi SV, Murray J, Simpson C, Shah SA, Robertson C, Sheikh A. The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment. J Glob Health 2021; 11:01010. [PMID: 35047182 PMCID: PMC8763336 DOI: 10.7189/jogh.11.01010] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Igor Rudan
- Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK
| | - Davies Adeloye
- Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK
| | | | - Josie Murray
- COVID-19 Surveillance Lead, Public Health Scotland, Fife, UK
| | - Colin Simpson
- School of Health, Wellington Faculty of Health, Victoria University of Wellington, New Zealand
- Usher Institute, The University of Edinburgh, Edinburgh, UK
| | | | - Chris Robertson
- Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK and Public Health Scotland, Glasgow, UK
| | - Aziz Sheikh
- Usher Institute, The University of Edinburgh, Edinburgh, UK
| | - EAVE II collaboration
- Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK
- MRC/CSO Social & Public Health Sciences Unit, Glasgow, UK
- COVID-19 Surveillance Lead, Public Health Scotland, Fife, UK
- School of Health, Wellington Faculty of Health, Victoria University of Wellington, New Zealand
- Usher Institute, The University of Edinburgh, Edinburgh, UK
- Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK and Public Health Scotland, Glasgow, UK
| |
Collapse
|